

Remarks

Claims 1, 2, 3, 4, 5, 6 and 8 are pending. Claims 1, 5 and 8 have been amended. Claims 7, 9 and 10-17 have been cancelled.

Election/Restriction

Applicants wish to provisionally elect without traverse Group II, which are claims 1-9, drawn to a method of treating myeloma. Independent claim 1 has been amended to define methods of treating a warm-blooded animal having myeloma comprising epothilone B. Therefore, the species elected is epothilone B. Applicants reserve the right to file a divisional application pertaining to the subject matter in Group II.

Entry of this Response is respectfully requested.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
Oona A. Manzari  
Attorney for Applicant  
Reg. No. 48,152

Date: 12/19/07